nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—obesity	0.159	0.445	CbGaD
Thalidomide—CYP2E1—obesity	0.122	0.343	CbGaD
Thalidomide—PTGS2—obesity	0.0753	0.212	CbGaD
Thalidomide—CYP2E1—Bupropion—obesity	0.0431	0.145	CbGbCtD
Thalidomide—CYP2E1—Cimetidine—obesity	0.0316	0.106	CbGbCtD
Thalidomide—CYP1A2—Phentermine—obesity	0.0293	0.0984	CbGbCtD
Thalidomide—CYP1A2—Phenylpropanolamine—obesity	0.028	0.0938	CbGbCtD
Thalidomide—CYP2C9—Phentermine—obesity	0.0264	0.0886	CbGbCtD
Thalidomide—CYP1A2—Bupropion—obesity	0.0249	0.0836	CbGbCtD
Thalidomide—CYP3A5—Cimetidine—obesity	0.0246	0.0825	CbGbCtD
Thalidomide—CYP2C9—Bupropion—obesity	0.0225	0.0754	CbGbCtD
Thalidomide—CYP2C19—Cimetidine—obesity	0.0198	0.0665	CbGbCtD
Thalidomide—CYP1A2—Cimetidine—obesity	0.0183	0.0614	CbGbCtD
Thalidomide—CYP2C9—Cimetidine—obesity	0.0165	0.0553	CbGbCtD
Thalidomide—CYP2C19—Topiramate—obesity	0.013	0.0436	CbGbCtD
Thalidomide—PTGS2—ovarian follicle—obesity	0.00293	0.0653	CbGeAlD
Thalidomide—FGFR2—hindbrain—obesity	0.00208	0.0464	CbGeAlD
Thalidomide—NFKB1—islet of Langerhans—obesity	0.00179	0.04	CbGeAlD
Thalidomide—NFKB1—respiratory system—obesity	0.00169	0.0378	CbGeAlD
Thalidomide—CRBN—islet of Langerhans—obesity	0.0015	0.0335	CbGeAlD
Thalidomide—CRBN—respiratory system—obesity	0.00142	0.0316	CbGeAlD
Thalidomide—NFKB1—cardiovascular system—obesity	0.0013	0.0289	CbGeAlD
Thalidomide—FGFR2—respiratory system—obesity	0.00127	0.0284	CbGeAlD
Thalidomide—CRBN—adrenal cortex—obesity	0.00119	0.0266	CbGeAlD
Thalidomide—NFKB1—pituitary gland—obesity	0.00115	0.0256	CbGeAlD
Thalidomide—NFKB1—adipose tissue—obesity	0.00114	0.0255	CbGeAlD
Thalidomide—NFKB1—digestive system—obesity	0.00108	0.024	CbGeAlD
Thalidomide—NFKB1—adrenal gland—obesity	0.00103	0.0229	CbGeAlD
Thalidomide—FGFR2—cardiovascular system—obesity	0.000975	0.0217	CbGeAlD
Thalidomide—CRBN—pituitary gland—obesity	0.000963	0.0215	CbGeAlD
Thalidomide—CRBN—adipose tissue—obesity	0.000959	0.0214	CbGeAlD
Thalidomide—CRBN—digestive system—obesity	0.000903	0.0201	CbGeAlD
Thalidomide—NFKB1—endocrine gland—obesity	0.00089	0.0198	CbGeAlD
Thalidomide—CRBN—adrenal gland—obesity	0.000861	0.0192	CbGeAlD
Thalidomide—FGFR2—adipose tissue—obesity	0.00086	0.0192	CbGeAlD
Thalidomide—FGFR2—digestive system—obesity	0.000809	0.018	CbGeAlD
Thalidomide—NFKB1—liver—obesity	0.000803	0.0179	CbGeAlD
Thalidomide—FGFR2—adrenal gland—obesity	0.000771	0.0172	CbGeAlD
Thalidomide—Pomalidomide—TNF—obesity	0.000771	0.21	CrCbGaD
Thalidomide—CRBN—endocrine gland—obesity	0.000746	0.0166	CbGeAlD
Thalidomide—Menadione—NQO1—obesity	0.000719	0.196	CrCbGaD
Thalidomide—Menadione—F2—obesity	0.0007	0.191	CrCbGaD
Thalidomide—CRBN—liver—obesity	0.000673	0.015	CbGeAlD
Thalidomide—FGFR2—endocrine gland—obesity	0.000669	0.0149	CbGeAlD
Thalidomide—PTGS2—gall bladder—obesity	0.000625	0.0139	CbGeAlD
Thalidomide—FGFR2—liver—obesity	0.000603	0.0134	CbGeAlD
Thalidomide—CYP3A5—islet of Langerhans—obesity	0.000477	0.0106	CbGeAlD
Thalidomide—CYP1A2—respiratory system—obesity	0.000467	0.0104	CbGeAlD
Thalidomide—CYP1A1—respiratory system—obesity	0.000461	0.0103	CbGeAlD
Thalidomide—CYP3A5—respiratory system—obesity	0.00045	0.01	CbGeAlD
Thalidomide—Menadione—MTHFR—obesity	0.000448	0.122	CrCbGaD
Thalidomide—CYP2E1—respiratory system—obesity	0.00042	0.00936	CbGeAlD
Thalidomide—PTGS2—islet of Langerhans—obesity	0.00041	0.00913	CbGeAlD
Thalidomide—PTGS1—respiratory system—obesity	0.000405	0.00902	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—obesity	0.000394	0.107	CrCbGaD
Thalidomide—PTGS2—respiratory system—obesity	0.000387	0.00862	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—obesity	0.000366	0.0998	CrCbGaD
Thalidomide—CYP2C19—digestive system—obesity	0.000364	0.0081	CbGeAlD
Thalidomide—CYP2C9—cardiovascular system—obesity	0.00034	0.00756	CbGeAlD
Thalidomide—PTGS2—adrenal cortex—obesity	0.000325	0.00723	CbGeAlD
Thalidomide—CYP2E1—cardiovascular system—obesity	0.000322	0.00717	CbGeAlD
Thalidomide—CYP1A1—adipose tissue—obesity	0.000311	0.00693	CbGeAlD
Thalidomide—PTGS1—cardiovascular system—obesity	0.00031	0.0069	CbGeAlD
Thalidomide—CYP3A5—adipose tissue—obesity	0.000304	0.00678	CbGeAlD
Thalidomide—CYP2C19—endocrine gland—obesity	0.0003	0.00669	CbGeAlD
Thalidomide—CYP1A2—digestive system—obesity	0.000297	0.00661	CbGeAlD
Thalidomide—PTGS2—cardiovascular system—obesity	0.000296	0.0066	CbGeAlD
Thalidomide—CYP1A1—digestive system—obesity	0.000293	0.00652	CbGeAlD
Thalidomide—CYP3A5—digestive system—obesity	0.000286	0.00638	CbGeAlD
Thalidomide—CYP2C9—digestive system—obesity	0.000282	0.00628	CbGeAlD
Thalidomide—PTGS1—pituitary gland—obesity	0.000274	0.00611	CbGeAlD
Thalidomide—PTGS1—adipose tissue—obesity	0.000273	0.00609	CbGeAlD
Thalidomide—Menadione—CYP2E1—obesity	0.000273	0.0743	CrCbGaD
Thalidomide—CYP2C19—liver—obesity	0.000271	0.00603	CbGeAlD
Thalidomide—CYP2E1—digestive system—obesity	0.000267	0.00595	CbGeAlD
Thalidomide—PTGS2—pituitary gland—obesity	0.000262	0.00584	CbGeAlD
Thalidomide—PTGS2—adipose tissue—obesity	0.000261	0.00582	CbGeAlD
Thalidomide—PTGS1—digestive system—obesity	0.000257	0.00573	CbGeAlD
Thalidomide—CYP2E1—adrenal gland—obesity	0.000254	0.00567	CbGeAlD
Thalidomide—PTGS2—digestive system—obesity	0.000246	0.00548	CbGeAlD
Thalidomide—CYP1A2—endocrine gland—obesity	0.000245	0.00547	CbGeAlD
Thalidomide—PTGS1—adrenal gland—obesity	0.000245	0.00546	CbGeAlD
Thalidomide—CYP1A1—endocrine gland—obesity	0.000242	0.00539	CbGeAlD
Thalidomide—CYP3A5—endocrine gland—obesity	0.000237	0.00527	CbGeAlD
Thalidomide—PTGS2—adrenal gland—obesity	0.000234	0.00522	CbGeAlD
Thalidomide—CYP2C9—endocrine gland—obesity	0.000233	0.00519	CbGeAlD
Thalidomide—CYP1A2—liver—obesity	0.000221	0.00493	CbGeAlD
Thalidomide—CYP2E1—endocrine gland—obesity	0.000221	0.00492	CbGeAlD
Thalidomide—CYP1A1—liver—obesity	0.000218	0.00486	CbGeAlD
Thalidomide—CYP3A5—liver—obesity	0.000213	0.00475	CbGeAlD
Thalidomide—PTGS1—endocrine gland—obesity	0.000213	0.00474	CbGeAlD
Thalidomide—CYP2C9—liver—obesity	0.00021	0.00468	CbGeAlD
Thalidomide—PTGS2—endocrine gland—obesity	0.000203	0.00453	CbGeAlD
Thalidomide—CYP2E1—liver—obesity	0.000199	0.00443	CbGeAlD
Thalidomide—PTGS2—liver—obesity	0.000183	0.00408	CbGeAlD
Thalidomide—Chest pain—Sibutramine—obesity	8.88e-05	0.000537	CcSEcCtD
Thalidomide—Myalgia—Sibutramine—obesity	8.88e-05	0.000537	CcSEcCtD
Thalidomide—Arthralgia—Sibutramine—obesity	8.88e-05	0.000537	CcSEcCtD
Thalidomide—Anxiety—Sibutramine—obesity	8.85e-05	0.000535	CcSEcCtD
Thalidomide—Nervousness—Bupropion—obesity	8.83e-05	0.000534	CcSEcCtD
Thalidomide—Oedema—Orlistat—obesity	8.79e-05	0.000531	CcSEcCtD
Thalidomide—Back pain—Bupropion—obesity	8.79e-05	0.000531	CcSEcCtD
Thalidomide—Orthostatic hypotension—Topiramate—obesity	8.78e-05	0.000531	CcSEcCtD
Thalidomide—Discomfort—Sibutramine—obesity	8.77e-05	0.00053	CcSEcCtD
Thalidomide—Hypokalaemia—Topiramate—obesity	8.75e-05	0.000529	CcSEcCtD
Thalidomide—Muscle spasms—Bupropion—obesity	8.74e-05	0.000528	CcSEcCtD
Thalidomide—Infection—Orlistat—obesity	8.74e-05	0.000528	CcSEcCtD
Thalidomide—Breast disorder—Topiramate—obesity	8.69e-05	0.000525	CcSEcCtD
Thalidomide—Dry mouth—Sibutramine—obesity	8.68e-05	0.000525	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Topiramate—obesity	8.66e-05	0.000523	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Topiramate—obesity	8.66e-05	0.000523	CcSEcCtD
Thalidomide—Nervous system disorder—Orlistat—obesity	8.62e-05	0.000521	CcSEcCtD
Thalidomide—Confusional state—Sibutramine—obesity	8.58e-05	0.000519	CcSEcCtD
Thalidomide—Vision blurred—Bupropion—obesity	8.57e-05	0.000518	CcSEcCtD
Thalidomide—Skin disorder—Orlistat—obesity	8.54e-05	0.000516	CcSEcCtD
Thalidomide—Tremor—Bupropion—obesity	8.52e-05	0.000515	CcSEcCtD
Thalidomide—Oedema—Sibutramine—obesity	8.51e-05	0.000514	CcSEcCtD
Thalidomide—Hyperhidrosis—Orlistat—obesity	8.5e-05	0.000514	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Topiramate—obesity	8.48e-05	0.000513	CcSEcCtD
Thalidomide—Muscular weakness—Topiramate—obesity	8.48e-05	0.000513	CcSEcCtD
Thalidomide—Infection—Sibutramine—obesity	8.46e-05	0.000511	CcSEcCtD
Thalidomide—Ill-defined disorder—Bupropion—obesity	8.44e-05	0.00051	CcSEcCtD
Thalidomide—Anaemia—Bupropion—obesity	8.4e-05	0.000508	CcSEcCtD
Thalidomide—Shock—Sibutramine—obesity	8.37e-05	0.000506	CcSEcCtD
Thalidomide—Abdominal distension—Topiramate—obesity	8.37e-05	0.000506	CcSEcCtD
Thalidomide—Agitation—Bupropion—obesity	8.36e-05	0.000505	CcSEcCtD
Thalidomide—Thrombocytopenia—Sibutramine—obesity	8.33e-05	0.000504	CcSEcCtD
Thalidomide—Dysphagia—Topiramate—obesity	8.31e-05	0.000502	CcSEcCtD
Thalidomide—Angioedema—Bupropion—obesity	8.31e-05	0.000502	CcSEcCtD
Thalidomide—Tachycardia—Sibutramine—obesity	8.31e-05	0.000502	CcSEcCtD
Thalidomide—Skin disorder—Sibutramine—obesity	8.27e-05	0.0005	CcSEcCtD
Thalidomide—Eosinophilia—Topiramate—obesity	8.23e-05	0.000497	CcSEcCtD
Thalidomide—Hyperhidrosis—Sibutramine—obesity	8.23e-05	0.000497	CcSEcCtD
Thalidomide—Malaise—Bupropion—obesity	8.2e-05	0.000495	CcSEcCtD
Thalidomide—Vertigo—Bupropion—obesity	8.17e-05	0.000494	CcSEcCtD
Thalidomide—Syncope—Bupropion—obesity	8.15e-05	0.000493	CcSEcCtD
Thalidomide—Pancreatitis—Topiramate—obesity	8.15e-05	0.000493	CcSEcCtD
Thalidomide—Leukopenia—Bupropion—obesity	8.14e-05	0.000492	CcSEcCtD
Thalidomide—Anorexia—Sibutramine—obesity	8.11e-05	0.00049	CcSEcCtD
Thalidomide—Angina pectoris—Topiramate—obesity	8.1e-05	0.000489	CcSEcCtD
Thalidomide—Palpitations—Bupropion—obesity	8.03e-05	0.000486	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Orlistat—obesity	8.01e-05	0.000484	CcSEcCtD
Thalidomide—Bronchitis—Topiramate—obesity	7.99e-05	0.000483	CcSEcCtD
Thalidomide—Loss of consciousness—Bupropion—obesity	7.99e-05	0.000483	CcSEcCtD
Thalidomide—Insomnia—Orlistat—obesity	7.95e-05	0.000481	CcSEcCtD
Thalidomide—Hypotension—Sibutramine—obesity	7.95e-05	0.000481	CcSEcCtD
Thalidomide—Cough—Bupropion—obesity	7.93e-05	0.000479	CcSEcCtD
Thalidomide—Paraesthesia—Orlistat—obesity	7.9e-05	0.000477	CcSEcCtD
Thalidomide—Pancytopenia—Topiramate—obesity	7.89e-05	0.000477	CcSEcCtD
Thalidomide—Convulsion—Bupropion—obesity	7.88e-05	0.000476	CcSEcCtD
Thalidomide—Hypertension—Bupropion—obesity	7.85e-05	0.000474	CcSEcCtD
Thalidomide—Neutropenia—Topiramate—obesity	7.77e-05	0.00047	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Sibutramine—obesity	7.75e-05	0.000469	CcSEcCtD
Thalidomide—Dyspepsia—Orlistat—obesity	7.74e-05	0.000468	CcSEcCtD
Thalidomide—Chest pain—Bupropion—obesity	7.74e-05	0.000468	CcSEcCtD
Thalidomide—Arthralgia—Bupropion—obesity	7.74e-05	0.000468	CcSEcCtD
Thalidomide—Myalgia—Bupropion—obesity	7.74e-05	0.000468	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Topiramate—obesity	7.73e-05	0.000467	CcSEcCtD
Thalidomide—Anxiety—Bupropion—obesity	7.71e-05	0.000466	CcSEcCtD
Thalidomide—Insomnia—Sibutramine—obesity	7.7e-05	0.000465	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	7.69e-05	0.000465	CcSEcCtD
Thalidomide—Pollakiuria—Topiramate—obesity	7.68e-05	0.000464	CcSEcCtD
Thalidomide—Erectile dysfunction—Topiramate—obesity	7.66e-05	0.000463	CcSEcCtD
Thalidomide—Discomfort—Bupropion—obesity	7.65e-05	0.000462	CcSEcCtD
Thalidomide—Decreased appetite—Orlistat—obesity	7.65e-05	0.000462	CcSEcCtD
Thalidomide—Paraesthesia—Sibutramine—obesity	7.64e-05	0.000462	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Orlistat—obesity	7.59e-05	0.000459	CcSEcCtD
Thalidomide—Dyspnoea—Sibutramine—obesity	7.59e-05	0.000459	CcSEcCtD
Thalidomide—Photosensitivity reaction—Topiramate—obesity	7.59e-05	0.000459	CcSEcCtD
Thalidomide—Fatigue—Orlistat—obesity	7.58e-05	0.000458	CcSEcCtD
Thalidomide—Dry mouth—Bupropion—obesity	7.57e-05	0.000457	CcSEcCtD
Thalidomide—Somnolence—Sibutramine—obesity	7.57e-05	0.000457	CcSEcCtD
Thalidomide—Weight increased—Topiramate—obesity	7.57e-05	0.000457	CcSEcCtD
Thalidomide—Weight decreased—Topiramate—obesity	7.52e-05	0.000455	CcSEcCtD
Thalidomide—Pain—Orlistat—obesity	7.52e-05	0.000454	CcSEcCtD
Thalidomide—Hyperglycaemia—Topiramate—obesity	7.5e-05	0.000453	CcSEcCtD
Thalidomide—Dyspepsia—Sibutramine—obesity	7.49e-05	0.000453	CcSEcCtD
Thalidomide—Confusional state—Bupropion—obesity	7.48e-05	0.000452	CcSEcCtD
Thalidomide—Pneumonia—Topiramate—obesity	7.46e-05	0.000451	CcSEcCtD
Thalidomide—Oedema—Bupropion—obesity	7.42e-05	0.000448	CcSEcCtD
Thalidomide—Infestation NOS—Topiramate—obesity	7.41e-05	0.000448	CcSEcCtD
Thalidomide—Infestation—Topiramate—obesity	7.41e-05	0.000448	CcSEcCtD
Thalidomide—Decreased appetite—Sibutramine—obesity	7.4e-05	0.000447	CcSEcCtD
Thalidomide—Depression—Topiramate—obesity	7.39e-05	0.000447	CcSEcCtD
Thalidomide—Infection—Bupropion—obesity	7.37e-05	0.000445	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Topiramate—obesity	7.35e-05	0.000444	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Sibutramine—obesity	7.35e-05	0.000444	CcSEcCtD
Thalidomide—Shock—Bupropion—obesity	7.3e-05	0.000441	CcSEcCtD
Thalidomide—Renal failure—Topiramate—obesity	7.29e-05	0.00044	CcSEcCtD
Thalidomide—Pain—Sibutramine—obesity	7.28e-05	0.00044	CcSEcCtD
Thalidomide—Constipation—Sibutramine—obesity	7.28e-05	0.00044	CcSEcCtD
Thalidomide—Nervous system disorder—Bupropion—obesity	7.28e-05	0.00044	CcSEcCtD
Thalidomide—Neuropathy peripheral—Topiramate—obesity	7.27e-05	0.000439	CcSEcCtD
Thalidomide—Thrombocytopenia—Bupropion—obesity	7.27e-05	0.000439	CcSEcCtD
Thalidomide—Feeling abnormal—Orlistat—obesity	7.25e-05	0.000438	CcSEcCtD
Thalidomide—Tachycardia—Bupropion—obesity	7.24e-05	0.000438	CcSEcCtD
Thalidomide—Stomatitis—Topiramate—obesity	7.23e-05	0.000437	CcSEcCtD
Thalidomide—Skin disorder—Bupropion—obesity	7.21e-05	0.000436	CcSEcCtD
Thalidomide—Conjunctivitis—Topiramate—obesity	7.2e-05	0.000435	CcSEcCtD
Thalidomide—Gastrointestinal pain—Orlistat—obesity	7.19e-05	0.000435	CcSEcCtD
Thalidomide—Hyperhidrosis—Bupropion—obesity	7.17e-05	0.000433	CcSEcCtD
Thalidomide—Anorexia—Bupropion—obesity	7.07e-05	0.000427	CcSEcCtD
Thalidomide—Haematuria—Topiramate—obesity	7.07e-05	0.000427	CcSEcCtD
Thalidomide—Feeling abnormal—Sibutramine—obesity	7.01e-05	0.000424	CcSEcCtD
Thalidomide—Epistaxis—Topiramate—obesity	6.99e-05	0.000422	CcSEcCtD
Thalidomide—Urticaria—Orlistat—obesity	6.99e-05	0.000422	CcSEcCtD
Thalidomide—Gastrointestinal pain—Sibutramine—obesity	6.96e-05	0.000421	CcSEcCtD
Thalidomide—Sinusitis—Topiramate—obesity	6.95e-05	0.00042	CcSEcCtD
Thalidomide—Body temperature increased—Orlistat—obesity	6.95e-05	0.00042	CcSEcCtD
Thalidomide—Abdominal pain—Orlistat—obesity	6.95e-05	0.00042	CcSEcCtD
Thalidomide—Hypotension—Bupropion—obesity	6.93e-05	0.000419	CcSEcCtD
Thalidomide—Agranulocytosis—Topiramate—obesity	6.92e-05	0.000418	CcSEcCtD
Thalidomide—Bradycardia—Topiramate—obesity	6.77e-05	0.000409	CcSEcCtD
Thalidomide—Urticaria—Sibutramine—obesity	6.76e-05	0.000409	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Bupropion—obesity	6.76e-05	0.000409	CcSEcCtD
Thalidomide—Body temperature increased—Sibutramine—obesity	6.73e-05	0.000407	CcSEcCtD
Thalidomide—Abdominal pain—Sibutramine—obesity	6.73e-05	0.000407	CcSEcCtD
Thalidomide—Insomnia—Bupropion—obesity	6.71e-05	0.000406	CcSEcCtD
Thalidomide—Rhinitis—Topiramate—obesity	6.67e-05	0.000403	CcSEcCtD
Thalidomide—Paraesthesia—Bupropion—obesity	6.66e-05	0.000403	CcSEcCtD
Thalidomide—Hepatitis—Topiramate—obesity	6.65e-05	0.000402	CcSEcCtD
Thalidomide—Hypoaesthesia—Topiramate—obesity	6.62e-05	0.0004	CcSEcCtD
Thalidomide—Dyspnoea—Bupropion—obesity	6.62e-05	0.0004	CcSEcCtD
Thalidomide—Pharyngitis—Topiramate—obesity	6.6e-05	0.000399	CcSEcCtD
Thalidomide—Somnolence—Bupropion—obesity	6.6e-05	0.000399	CcSEcCtD
Thalidomide—Urinary tract disorder—Topiramate—obesity	6.57e-05	0.000397	CcSEcCtD
Thalidomide—Oedema peripheral—Topiramate—obesity	6.55e-05	0.000396	CcSEcCtD
Thalidomide—Dyspepsia—Bupropion—obesity	6.53e-05	0.000395	CcSEcCtD
Thalidomide—Urethral disorder—Topiramate—obesity	6.52e-05	0.000394	CcSEcCtD
Thalidomide—Hypersensitivity—Orlistat—obesity	6.48e-05	0.000392	CcSEcCtD
Thalidomide—Decreased appetite—Bupropion—obesity	6.45e-05	0.00039	CcSEcCtD
Thalidomide—Visual impairment—Topiramate—obesity	6.41e-05	0.000388	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Bupropion—obesity	6.41e-05	0.000387	CcSEcCtD
Thalidomide—Fatigue—Bupropion—obesity	6.4e-05	0.000387	CcSEcCtD
Thalidomide—Pain—Bupropion—obesity	6.35e-05	0.000383	CcSEcCtD
Thalidomide—Constipation—Bupropion—obesity	6.35e-05	0.000383	CcSEcCtD
Thalidomide—Asthenia—Orlistat—obesity	6.31e-05	0.000381	CcSEcCtD
Thalidomide—Erythema multiforme—Topiramate—obesity	6.29e-05	0.00038	CcSEcCtD
Thalidomide—Hypersensitivity—Sibutramine—obesity	6.27e-05	0.000379	CcSEcCtD
Thalidomide—Pruritus—Orlistat—obesity	6.22e-05	0.000376	CcSEcCtD
Thalidomide—Eye disorder—Topiramate—obesity	6.22e-05	0.000376	CcSEcCtD
Thalidomide—Tinnitus—Topiramate—obesity	6.2e-05	0.000375	CcSEcCtD
Thalidomide—Cardiac disorder—Topiramate—obesity	6.18e-05	0.000373	CcSEcCtD
Thalidomide—Feeling abnormal—Bupropion—obesity	6.11e-05	0.00037	CcSEcCtD
Thalidomide—Asthenia—Sibutramine—obesity	6.11e-05	0.000369	CcSEcCtD
Thalidomide—Gastrointestinal pain—Bupropion—obesity	6.07e-05	0.000367	CcSEcCtD
Thalidomide—Angiopathy—Topiramate—obesity	6.04e-05	0.000365	CcSEcCtD
Thalidomide—Pruritus—Sibutramine—obesity	6.02e-05	0.000364	CcSEcCtD
Thalidomide—Diarrhoea—Orlistat—obesity	6.02e-05	0.000364	CcSEcCtD
Thalidomide—Immune system disorder—Topiramate—obesity	6.01e-05	0.000363	CcSEcCtD
Thalidomide—Mediastinal disorder—Topiramate—obesity	6e-05	0.000362	CcSEcCtD
Thalidomide—Chills—Topiramate—obesity	5.97e-05	0.000361	CcSEcCtD
Thalidomide—Urticaria—Bupropion—obesity	5.89e-05	0.000356	CcSEcCtD
Thalidomide—Alopecia—Topiramate—obesity	5.88e-05	0.000355	CcSEcCtD
Thalidomide—Abdominal pain—Bupropion—obesity	5.87e-05	0.000354	CcSEcCtD
Thalidomide—Body temperature increased—Bupropion—obesity	5.87e-05	0.000354	CcSEcCtD
Thalidomide—Mental disorder—Topiramate—obesity	5.83e-05	0.000352	CcSEcCtD
Thalidomide—Diarrhoea—Sibutramine—obesity	5.82e-05	0.000352	CcSEcCtD
Thalidomide—Dizziness—Orlistat—obesity	5.82e-05	0.000351	CcSEcCtD
Thalidomide—Malnutrition—Topiramate—obesity	5.79e-05	0.00035	CcSEcCtD
Thalidomide—Flatulence—Topiramate—obesity	5.71e-05	0.000345	CcSEcCtD
Thalidomide—Tension—Topiramate—obesity	5.68e-05	0.000343	CcSEcCtD
Thalidomide—Dysgeusia—Topiramate—obesity	5.67e-05	0.000343	CcSEcCtD
Thalidomide—Dizziness—Sibutramine—obesity	5.63e-05	0.00034	CcSEcCtD
Thalidomide—Nervousness—Topiramate—obesity	5.63e-05	0.00034	CcSEcCtD
Thalidomide—Back pain—Topiramate—obesity	5.6e-05	0.000339	CcSEcCtD
Thalidomide—Vomiting—Orlistat—obesity	5.59e-05	0.000338	CcSEcCtD
Thalidomide—Muscle spasms—Topiramate—obesity	5.57e-05	0.000337	CcSEcCtD
Thalidomide—Rash—Orlistat—obesity	5.55e-05	0.000335	CcSEcCtD
Thalidomide—Dermatitis—Orlistat—obesity	5.54e-05	0.000335	CcSEcCtD
Thalidomide—Headache—Orlistat—obesity	5.51e-05	0.000333	CcSEcCtD
Thalidomide—Hypersensitivity—Bupropion—obesity	5.47e-05	0.00033	CcSEcCtD
Thalidomide—Vision blurred—Topiramate—obesity	5.46e-05	0.00033	CcSEcCtD
Thalidomide—Tremor—Topiramate—obesity	5.43e-05	0.000328	CcSEcCtD
Thalidomide—Vomiting—Sibutramine—obesity	5.41e-05	0.000327	CcSEcCtD
Thalidomide—Ill-defined disorder—Topiramate—obesity	5.37e-05	0.000325	CcSEcCtD
Thalidomide—Rash—Sibutramine—obesity	5.37e-05	0.000324	CcSEcCtD
Thalidomide—Dermatitis—Sibutramine—obesity	5.36e-05	0.000324	CcSEcCtD
Thalidomide—Anaemia—Topiramate—obesity	5.35e-05	0.000324	CcSEcCtD
Thalidomide—Headache—Sibutramine—obesity	5.33e-05	0.000322	CcSEcCtD
Thalidomide—Asthenia—Bupropion—obesity	5.32e-05	0.000322	CcSEcCtD
Thalidomide—Agitation—Topiramate—obesity	5.32e-05	0.000322	CcSEcCtD
Thalidomide—Pruritus—Bupropion—obesity	5.25e-05	0.000317	CcSEcCtD
Thalidomide—Nausea—Orlistat—obesity	5.22e-05	0.000316	CcSEcCtD
Thalidomide—Malaise—Topiramate—obesity	5.22e-05	0.000316	CcSEcCtD
Thalidomide—Vertigo—Topiramate—obesity	5.2e-05	0.000314	CcSEcCtD
Thalidomide—Syncope—Topiramate—obesity	5.19e-05	0.000314	CcSEcCtD
Thalidomide—Leukopenia—Topiramate—obesity	5.18e-05	0.000313	CcSEcCtD
Thalidomide—Palpitations—Topiramate—obesity	5.12e-05	0.000309	CcSEcCtD
Thalidomide—Loss of consciousness—Topiramate—obesity	5.09e-05	0.000308	CcSEcCtD
Thalidomide—Diarrhoea—Bupropion—obesity	5.08e-05	0.000307	CcSEcCtD
Thalidomide—Nausea—Sibutramine—obesity	5.06e-05	0.000306	CcSEcCtD
Thalidomide—Cough—Topiramate—obesity	5.05e-05	0.000305	CcSEcCtD
Thalidomide—Convulsion—Topiramate—obesity	5.02e-05	0.000303	CcSEcCtD
Thalidomide—Hypertension—Topiramate—obesity	5e-05	0.000302	CcSEcCtD
Thalidomide—Chest pain—Topiramate—obesity	4.93e-05	0.000298	CcSEcCtD
Thalidomide—Arthralgia—Topiramate—obesity	4.93e-05	0.000298	CcSEcCtD
Thalidomide—Myalgia—Topiramate—obesity	4.93e-05	0.000298	CcSEcCtD
Thalidomide—Anxiety—Topiramate—obesity	4.91e-05	0.000297	CcSEcCtD
Thalidomide—Dizziness—Bupropion—obesity	4.91e-05	0.000297	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	4.9e-05	0.000296	CcSEcCtD
Thalidomide—Discomfort—Topiramate—obesity	4.87e-05	0.000294	CcSEcCtD
Thalidomide—Dry mouth—Topiramate—obesity	4.82e-05	0.000291	CcSEcCtD
Thalidomide—Confusional state—Topiramate—obesity	4.77e-05	0.000288	CcSEcCtD
Thalidomide—Oedema—Topiramate—obesity	4.73e-05	0.000286	CcSEcCtD
Thalidomide—Vomiting—Bupropion—obesity	4.72e-05	0.000285	CcSEcCtD
Thalidomide—Infection—Topiramate—obesity	4.7e-05	0.000284	CcSEcCtD
Thalidomide—Rash—Bupropion—obesity	4.68e-05	0.000283	CcSEcCtD
Thalidomide—Dermatitis—Bupropion—obesity	4.67e-05	0.000282	CcSEcCtD
Thalidomide—Shock—Topiramate—obesity	4.65e-05	0.000281	CcSEcCtD
Thalidomide—Headache—Bupropion—obesity	4.65e-05	0.000281	CcSEcCtD
Thalidomide—Nervous system disorder—Topiramate—obesity	4.64e-05	0.00028	CcSEcCtD
Thalidomide—Thrombocytopenia—Topiramate—obesity	4.63e-05	0.00028	CcSEcCtD
Thalidomide—Tachycardia—Topiramate—obesity	4.61e-05	0.000279	CcSEcCtD
Thalidomide—Skin disorder—Topiramate—obesity	4.59e-05	0.000277	CcSEcCtD
Thalidomide—Hyperhidrosis—Topiramate—obesity	4.57e-05	0.000276	CcSEcCtD
Thalidomide—Anorexia—Topiramate—obesity	4.51e-05	0.000272	CcSEcCtD
Thalidomide—Hypotension—Topiramate—obesity	4.42e-05	0.000267	CcSEcCtD
Thalidomide—Nausea—Bupropion—obesity	4.41e-05	0.000266	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Topiramate—obesity	4.31e-05	0.00026	CcSEcCtD
Thalidomide—Insomnia—Topiramate—obesity	4.28e-05	0.000258	CcSEcCtD
Thalidomide—Paraesthesia—Topiramate—obesity	4.24e-05	0.000257	CcSEcCtD
Thalidomide—Dyspnoea—Topiramate—obesity	4.21e-05	0.000255	CcSEcCtD
Thalidomide—Somnolence—Topiramate—obesity	4.2e-05	0.000254	CcSEcCtD
Thalidomide—Dyspepsia—Topiramate—obesity	4.16e-05	0.000251	CcSEcCtD
Thalidomide—Decreased appetite—Topiramate—obesity	4.11e-05	0.000248	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Topiramate—obesity	4.08e-05	0.000247	CcSEcCtD
Thalidomide—Fatigue—Topiramate—obesity	4.08e-05	0.000246	CcSEcCtD
Thalidomide—Pain—Topiramate—obesity	4.04e-05	0.000244	CcSEcCtD
Thalidomide—Constipation—Topiramate—obesity	4.04e-05	0.000244	CcSEcCtD
Thalidomide—Feeling abnormal—Topiramate—obesity	3.9e-05	0.000235	CcSEcCtD
Thalidomide—Gastrointestinal pain—Topiramate—obesity	3.87e-05	0.000234	CcSEcCtD
Thalidomide—Urticaria—Topiramate—obesity	3.76e-05	0.000227	CcSEcCtD
Thalidomide—Body temperature increased—Topiramate—obesity	3.74e-05	0.000226	CcSEcCtD
Thalidomide—Abdominal pain—Topiramate—obesity	3.74e-05	0.000226	CcSEcCtD
Thalidomide—Hypersensitivity—Topiramate—obesity	3.48e-05	0.00021	CcSEcCtD
Thalidomide—Asthenia—Topiramate—obesity	3.39e-05	0.000205	CcSEcCtD
Thalidomide—Pruritus—Topiramate—obesity	3.34e-05	0.000202	CcSEcCtD
Thalidomide—Diarrhoea—Topiramate—obesity	3.23e-05	0.000195	CcSEcCtD
Thalidomide—Dizziness—Topiramate—obesity	3.13e-05	0.000189	CcSEcCtD
Thalidomide—Vomiting—Topiramate—obesity	3.01e-05	0.000182	CcSEcCtD
Thalidomide—Rash—Topiramate—obesity	2.98e-05	0.00018	CcSEcCtD
Thalidomide—Dermatitis—Topiramate—obesity	2.98e-05	0.00018	CcSEcCtD
Thalidomide—Headache—Topiramate—obesity	2.96e-05	0.000179	CcSEcCtD
Thalidomide—Nausea—Topiramate—obesity	2.81e-05	0.00017	CcSEcCtD
Thalidomide—PTGS2—Metabolism—MTHFR—obesity	2.37e-06	1.79e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GGT1—obesity	2.36e-06	1.79e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT1—obesity	2.36e-06	1.79e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CETP—obesity	2.35e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CD36—obesity	2.35e-06	1.78e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—obesity	2.35e-06	1.78e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IRS1—obesity	2.35e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CD36—obesity	2.35e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2E1—obesity	2.34e-06	1.77e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LPL—obesity	2.33e-06	1.77e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SDC1—obesity	2.33e-06	1.76e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARA—obesity	2.32e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NCOA1—obesity	2.32e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NQO1—obesity	2.32e-06	1.75e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKR1C3—obesity	2.29e-06	1.73e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—STK11—obesity	2.29e-06	1.73e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP19A1—obesity	2.29e-06	1.73e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK8—obesity	2.29e-06	1.73e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX1—obesity	2.28e-06	1.72e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—obesity	2.27e-06	1.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—obesity	2.26e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SCARB1—obesity	2.25e-06	1.71e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AGT—obesity	2.25e-06	1.7e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—INS—obesity	2.25e-06	1.7e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—obesity	2.25e-06	1.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—obesity	2.23e-06	1.69e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—obesity	2.23e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—obesity	2.23e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—obesity	2.22e-06	1.68e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—obesity	2.22e-06	1.68e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GCG—obesity	2.22e-06	1.68e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A4—obesity	2.22e-06	1.68e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CD36—obesity	2.22e-06	1.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—obesity	2.2e-06	1.67e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CD—obesity	2.2e-06	1.67e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—obesity	2.19e-06	1.66e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYCS—obesity	2.19e-06	1.66e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SREBF1—obesity	2.19e-06	1.66e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARA—obesity	2.19e-06	1.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAV1—obesity	2.18e-06	1.65e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARA—obesity	2.18e-06	1.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOA1—obesity	2.18e-06	1.65e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—obesity	2.17e-06	1.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT2—obesity	2.17e-06	1.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK8—obesity	2.17e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT1—obesity	2.15e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GGT1—obesity	2.15e-06	1.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—obesity	2.14e-06	1.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT2—obesity	2.13e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—COMT—obesity	2.13e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AGT—obesity	2.12e-06	1.6e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NCOA1—obesity	2.12e-06	1.6e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AGT—obesity	2.11e-06	1.6e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—obesity	2.1e-06	1.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—obesity	2.1e-06	1.59e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNB3—obesity	2.1e-06	1.59e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARGC1A—obesity	2.1e-06	1.59e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—obesity	2.09e-06	1.58e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CD—obesity	2.09e-06	1.58e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—obesity	2.09e-06	1.58e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—STK11—obesity	2.09e-06	1.58e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP19A1—obesity	2.09e-06	1.58e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—obesity	2.09e-06	1.58e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—obesity	2.08e-06	1.58e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—FASN—obesity	2.08e-06	1.58e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3R1—obesity	2.08e-06	1.58e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—obesity	2.08e-06	1.58e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—obesity	2.08e-06	1.57e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—BCHE—obesity	2.07e-06	1.57e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—obesity	2.07e-06	1.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—obesity	2.07e-06	1.56e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARA—obesity	2.06e-06	1.56e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAV1—obesity	2.06e-06	1.56e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAV1—obesity	2.05e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOA1—obesity	2.05e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOA1—obesity	2.05e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNAS—obesity	2.04e-06	1.55e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TYK2—obesity	2.01e-06	1.52e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2E1—obesity	2e-06	1.51e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOB—obesity	2e-06	1.51e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AGT—obesity	2e-06	1.51e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RHOA—obesity	1.99e-06	1.51e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CG—obesity	1.99e-06	1.51e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—obesity	1.98e-06	1.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—obesity	1.98e-06	1.5e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NQO1—obesity	1.98e-06	1.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—obesity	1.98e-06	1.5e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—obesity	1.97e-06	1.49e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3R1—obesity	1.97e-06	1.49e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—obesity	1.96e-06	1.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—obesity	1.94e-06	1.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—COMT—obesity	1.94e-06	1.47e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAV1—obesity	1.94e-06	1.47e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—obesity	1.94e-06	1.47e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—obesity	1.94e-06	1.47e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOA1—obesity	1.93e-06	1.46e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CB—obesity	1.92e-06	1.45e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—obesity	1.92e-06	1.45e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—obesity	1.92e-06	1.45e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNB3—obesity	1.91e-06	1.45e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARGC1A—obesity	1.91e-06	1.45e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LPL—obesity	1.91e-06	1.45e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—obesity	1.9e-06	1.44e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—obesity	1.9e-06	1.44e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCG—obesity	1.9e-06	1.44e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A4—obesity	1.9e-06	1.44e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—obesity	1.89e-06	1.43e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—INS—obesity	1.88e-06	1.43e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CG—obesity	1.87e-06	1.42e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYCS—obesity	1.87e-06	1.42e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CG—obesity	1.87e-06	1.42e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX1—obesity	1.86e-06	1.41e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNAS—obesity	1.86e-06	1.41e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—obesity	1.85e-06	1.4e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—obesity	1.84e-06	1.4e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—obesity	1.84e-06	1.39e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GGT1—obesity	1.84e-06	1.39e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT1—obesity	1.84e-06	1.39e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—obesity	1.83e-06	1.38e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOB—obesity	1.82e-06	1.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTOR—obesity	1.82e-06	1.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CB—obesity	1.82e-06	1.38e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD36—obesity	1.81e-06	1.37e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NCOA1—obesity	1.81e-06	1.37e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—obesity	1.81e-06	1.37e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—obesity	1.8e-06	1.37e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—STK11—obesity	1.78e-06	1.35e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP19A1—obesity	1.78e-06	1.35e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—obesity	1.78e-06	1.35e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—obesity	1.78e-06	1.35e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—INS—obesity	1.77e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—INS—obesity	1.77e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CG—obesity	1.77e-06	1.34e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CD—obesity	1.75e-06	1.32e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LPL—obesity	1.74e-06	1.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—obesity	1.73e-06	1.31e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—obesity	1.72e-06	1.3e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—obesity	1.7e-06	1.29e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX1—obesity	1.7e-06	1.29e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARA—obesity	1.69e-06	1.28e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—obesity	1.68e-06	1.27e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—INS—obesity	1.67e-06	1.27e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—COMT—obesity	1.66e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD36—obesity	1.65e-06	1.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—obesity	1.65e-06	1.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3R1—obesity	1.65e-06	1.25e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—obesity	1.65e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CD—obesity	1.65e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CD—obesity	1.64e-06	1.24e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARGC1A—obesity	1.63e-06	1.24e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNB3—obesity	1.63e-06	1.24e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AGT—obesity	1.63e-06	1.24e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—obesity	1.63e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—obesity	1.63e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—obesity	1.62e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—obesity	1.6e-06	1.21e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNAS—obesity	1.59e-06	1.21e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAV1—obesity	1.59e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOA1—obesity	1.58e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—obesity	1.57e-06	1.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—obesity	1.56e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOB—obesity	1.56e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3R1—obesity	1.55e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—obesity	1.55e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CD—obesity	1.55e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—obesity	1.55e-06	1.17e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3R1—obesity	1.55e-06	1.17e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARA—obesity	1.54e-06	1.16e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—obesity	1.53e-06	1.16e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CB—obesity	1.52e-06	1.15e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—obesity	1.52e-06	1.15e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AGT—obesity	1.49e-06	1.13e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LPL—obesity	1.49e-06	1.13e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3R1—obesity	1.47e-06	1.11e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—obesity	1.47e-06	1.11e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—obesity	1.46e-06	1.11e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—obesity	1.46e-06	1.11e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX1—obesity	1.45e-06	1.1e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAV1—obesity	1.45e-06	1.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CG—obesity	1.44e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOA1—obesity	1.44e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CB—obesity	1.44e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CB—obesity	1.43e-06	1.08e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—obesity	1.42e-06	1.08e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—obesity	1.42e-06	1.07e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD36—obesity	1.41e-06	1.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—obesity	1.41e-06	1.07e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—obesity	1.39e-06	1.06e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—obesity	1.39e-06	1.05e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—obesity	1.38e-06	1.05e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—obesity	1.38e-06	1.04e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—INS—obesity	1.37e-06	1.04e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CB—obesity	1.35e-06	1.02e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—obesity	1.35e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—obesity	1.34e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—obesity	1.34e-06	1.01e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CG—obesity	1.32e-06	9.98e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARA—obesity	1.31e-06	9.95e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—obesity	1.31e-06	9.9e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—obesity	1.3e-06	9.87e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—obesity	1.28e-06	9.68e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AGT—obesity	1.27e-06	9.64e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—obesity	1.27e-06	9.63e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CD—obesity	1.27e-06	9.62e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—obesity	1.25e-06	9.5e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—obesity	1.25e-06	9.5e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—obesity	1.25e-06	9.45e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—INS—obesity	1.25e-06	9.44e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAV1—obesity	1.24e-06	9.36e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA1—obesity	1.23e-06	9.34e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3R1—obesity	1.2e-06	9.08e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—obesity	1.2e-06	9.08e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—obesity	1.18e-06	8.94e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—obesity	1.17e-06	8.86e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CD—obesity	1.16e-06	8.77e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—obesity	1.14e-06	8.66e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CG—obesity	1.13e-06	8.53e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—obesity	1.11e-06	8.4e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CB—obesity	1.11e-06	8.38e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—obesity	1.1e-06	8.31e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3R1—obesity	1.09e-06	8.28e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—obesity	1.09e-06	8.28e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—obesity	1.09e-06	8.23e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—obesity	1.07e-06	8.12e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—INS—obesity	1.07e-06	8.07e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CB—obesity	1.01e-06	7.64e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—obesity	1e-06	7.57e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CD—obesity	9.9e-07	7.49e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—obesity	9.83e-07	7.44e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—obesity	9.77e-07	7.4e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—obesity	9.56e-07	7.24e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3R1—obesity	9.35e-07	7.08e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—obesity	9.35e-07	7.08e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—obesity	9.29e-07	7.04e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—obesity	9.07e-07	6.86e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—obesity	8.75e-07	6.62e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—obesity	8.73e-07	6.61e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CB—obesity	8.63e-07	6.53e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—obesity	8.55e-07	6.47e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—obesity	8.25e-07	6.25e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—obesity	7.59e-07	5.75e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—obesity	7.15e-07	5.41e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—obesity	7.13e-07	5.4e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—obesity	6.75e-07	5.11e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—obesity	6.74e-07	5.1e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—obesity	6.15e-07	4.66e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—obesity	5.51e-07	4.18e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—obesity	5.26e-07	3.98e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—obesity	5.03e-07	3.81e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—obesity	4.3e-07	3.25e-06	CbGpPWpGaD
